RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stepped up their Corporate Presentation GamePaul has a lot riding on the Phase 3 protocol obtaining approval from FDA and maybe EMA .
I believe this is the first time that he has shown optimism in getting FDA''s spproval.
I must add that I am very pleased at Paul's reaffirming that he sees a great future with Trogarzo. Third quarter drop in total sales were a big disappointment for me and the market but Trogarzo s ssles still went up not down
The SP is behaving badly because of the big miss in Egrifta 3 rd quarter sales which decreases Paul's credibility.
A close to 18.5 - 19.5 sales revenue in the fourth quarter which I hope they pre announce and Fda greenlighting the Phase 3 trial will contribute to a more than doubling the SP in the Short Term
Continued sales success will gradually bring credibility back